Literature DB >> 25245119

Financial cost of amyotrophic lateral sclerosis: a case study.

M Obermann1, M Lyon.   

Abstract

There are only a few recently published reports of the cost of amyotrophic lateral sclerosis (ALS) care in the United States. Our objectives were to: 1) report annual and disease-duration costs; 2) provide costs related to specific care and services; 3) present costs by payor; and 4) identify strategies and resources that can be offered to patients to assist with the financial burden of ALS. Over a 10-year period (2001-2010), all expenses related to the cost of care for an individual patient were collected concurrently and then analyzed in 2012. Results showed that total disease-duration costs were $1,433,992 (85% paid by insurance, 9% paid by family, 6% paid by charities). The highest costs were for in-home caregivers ($669,150), ventilation ($212,430) and hospital care ($114,558). In conclusion, this case study illustrates costs of care for ALS as a burden for patients that may impact treatment decisions. Charity organizations and insurance case-managers provide services to patients that can help reduce this burden. Costs for specific services as well as resources identified by this study offer physicians and other healthcare providers data-based cost of care information and strategies to share with their patients.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; home care; patient care costs

Mesh:

Year:  2014        PMID: 25245119     DOI: 10.3109/21678421.2014.951946

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  7 in total

Review 1.  Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.

Authors:  Alan Moore; Carolyn A Young; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

2.  The economic burden of amyotrophic lateral sclerosis: a systematic review.

Authors:  K Achtert; L Kerkemeyer
Journal:  Eur J Health Econ       Date:  2021-06-18

3.  Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort study.

Authors:  Federica Edith Pisa; Giancarlo Logroscino; Paolo Giacomelli Battiston; Fabio Barbone
Journal:  BMC Pulm Med       Date:  2016-11-03       Impact factor: 3.317

4.  CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.

Authors:  Paul Mehta; D Kevin Horton; Edward J Kasarskis; Ed Tessaro; M Shira Eisenberg; Susan Laird; John Iskander
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-12-22       Impact factor: 17.586

5.  Treatment with penicillin G and hydrocortisone reduces ALS-associated symptoms: a case series of three patients.

Authors:  Bert Tuk; Harmen Jousma; Pieter J Gaillard
Journal:  F1000Res       Date:  2017-04-03

Review 6.  Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development.

Authors:  Spyros Papapetropoulos; Angela Pontius; Elizabeth Finger; Virginija Karrenbauer; David S Lynch; Matthew Brennan; Samantha Zappia; Wolfgang Koehler; Ludger Schoels; Stefanie N Hayer; Takuya Konno; Takeshi Ikeuchi; Troy Lund; Jennifer Orthmann-Murphy; Florian Eichler; Zbigniew K Wszolek
Journal:  Front Neurol       Date:  2022-02-03       Impact factor: 4.003

Review 7.  A perspective on persistent toxicants in veterans and amyotrophic lateral sclerosis: identifying exposures determining higher ALS risk.

Authors:  Diane B Re; Beizhan Yan; Lilian Calderón-Garcidueñas; Angeline S Andrew; Maeve Tischbein; Elijah W Stommel
Journal:  J Neurol       Date:  2022-01-01       Impact factor: 6.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.